CClinicalTrials.gg
TerminatedNCT06408350Updated Sep 2, 2026Results posted

Optimal Intervention to Full Viral Suppression: Text Me, Alexis!

An interventional study of Text Me, Alexis! in HIV, sponsored by Friends Research Institute, Inc.. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Friends Research Institute, Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
President Trump's Executive Order
Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alone, or PHN+SMS. Participants in the PHN alone and PHN+SMS arms will receive unlimited navigation sessions over 3 months. Participants in the SMS alone and PHN+SMS arms will receive 3 daily theory-based text messages for 90 days for a total of 270 unique scripted messages.

Read the detailed description

Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal (considering effectiveness and cost-effectiveness) intervention, or intervention combination for advancement along the HIV Care Continuum among trans women living with HIV (N=195). After screening, informed consent, and baseline assessment, participants will be randomized (1:1:1) into one of three arms: Peer Health Navigation (PHN) alone (n=65), SMS (text messaging) alone (n=65), or PHN+SMS (n=65). The study uses repeated assessments at baseline and at 3-, 6-, 12-, and 18-months post-enrollment, via an "intent-to-treat" design, where all assessments are administered to participants regardless of their engagement or retention. All intervention content is tailored and culturally responsive to trans women living with HIV.

Peer Health Navigation (PHN) alone. PHN is based on the theoretical foundation of Social Cognitive Theory. Participant-centered PHN helps to: (1) identify barriers to HIV care; (2) identify and link participants into needed auxiliary services; and (3) increase participants' self-efficacy in working with HIV care providers and other social service and treatment facilities. PHNs do not provide counseling or psychotherapy; rather, they work with each participant to successfully navigate complicated healthcare and social service systems. The PHN intervention utilizes an individualized, Participant-centered Treatment Plan with the specific goal of removing multiple and complex barriers that can impede linkage-to and retention-in HIV care, as well as the sustainment of medication adherence to achieve and maintain virological suppression. Each participant will work with a PHN to develop a Participant-centered Treatment Plan and get linked to HIV care or other needed auxiliary physical, mental health, and psychosocial services (e.g., hormone therapy, dental care, hepatitis testing/care, tuberculosis testing/care, substance use disorder treatment, mental health treatment, legal services, job training/development). If necessary, the PHN transports and accompanies the participant to and from her HIV care appointments (provision of transportation falls under the purview of PHN activities). The Participant-centered Treatment Plan identifies actions for the participant and PHN that must be taken by the next scheduled meeting, to help achieve short- and long-term goals, including participant access to needed behavioral health services, and advancement across the HIV Care Continuum. A priority of the first session is to schedule an HIV care appointment for the participant, if needed. The PHN also works with each participant to establish HIV self-efficacy regarding her treatment plan. Participants are introduced to a PHN immediately following randomization. PHN sessions are unlimited for 90 days.

Simple Message System (SMS [text messaging]) alone. Text messages are based on, and equally distributed across, three theories: Social Support Theory (SST), Social Cognitive Theory (SCT), and Health Belief Model (HBM). Participants receive three daily, theory-based text messages for 90 days (270 unique scripted messages), evenly arrayed across the three theories and the HIV Care Continuum. Text messages are scripted across: 1) HIV Care Continuum (HIV Positivity/Physical and Emotional Health, Linkage/Retention in HIV Care, and Antiretroviral Therapy (ART) Adherence/Viral Load Suppression); and, 2) theoretical foundation (SST, SCT, or HBM). Thus, each day participants receive one HIV Positivity/Physical and Emotional Health, one Linkage/Retention in HIV Care, and one ART Adherence/Viral Load Suppression message; each of which will be based on a theoretical foundation (SST, SCT, or HBM). Text messages are transmitted through gradual automation administration daily, including weekends, in real-time, within a 10-hour period, every five hours (e.g., at 12:00 PM, 5:00 PM, and 10:00 PM). Optimum hours were determined to be daily from 12:00 PM to 10:00 PM, though participants may personalize the schedule to any 10-hour period, and can choose to have the text messages delivered through their cell phone or email inbox. The automated text message delivery system was developed by Dimagi (dimagi.com). Dimagi designs clinical interfaces, health information systems, and mobile technologies to perform patient-level disease management, clinical decision support, and health system monitoring. To maintain interest and enthusiasm for the intervention, messages are systematically varied by theory and content, and participants never receive the same message twice. At the completion of the enrollment visit, a Research Assistant (RA) orients the participant to the SMS intervention.

PHN+SMS combined. Participants in the PHN+SMS arm will receive the same PHN and SMS interventions described above, but in concert to determine the effectiveness of the combined intervention when compared to PHN or SMS alone.

02

Conditions studied

  • HIV

Keywords

  • HIV
  • transgender women
  • peer health navigation
  • SMS, text messaging
  • economic evaluation
03

In context

Lead sponsor

Friends Research Institute, Inc. is the lead sponsor of 44 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Self-identified transgender woman;
  • Age 18 or older;
  • Verified HIV positive status;
  • Not currently in HIV care, and/or had not had an HIV care visit in the previous 6 months, and/or had a viral load of ≥200 copies/ml on her last lab test result, and/or not currently prescribed ART, and/or prescribed ART but does not rate her ability to take all her medications as "excellent";
  • Ability to receive daily text messages on either a personal cell phone or via an email account

Exclusion criteria

Exclusion Criteria:

  • Does not identify as a transgender woman;
  • Under 18 years of age;
  • HIV negative status;
  • Currently in HIV care, and had a HIV care visit in the previous 6 months, and had a viral load of ≤200 copies/ml on her last lab test result, and currently prescribed ART, and rates her ability to take all her medications as "excellent";
  • Does not have the ability to receive daily text messages on either a personal cell phone or via an email account.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Peer Health Navigation (PHN)

    PHN is a peer navigation intervention to advance trans women through the HIV Care Continuum by identifying their individual needs and barriers to HIV care, including: substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence. Participants receive unlimited navigation sessions over 3 months; PHN sessions are delivered in a private room similar to a one-on-one peer counseling session.

    Behavioral: Text Me, Alexis!

  • Experimental
    Simple Message System (SMS [text messaging])

    Text messages are scripted across: 1) HIV Care Continuum (HIV Positivity/Physical and Emotional Health, Linkage/Retention in HIV Care, and ART Adherence/Viral Load Suppression); and, 2) theoretical foundation (Social Support Theory, Social Cognitive Theory, or Health Belief Model). Participants receive three daily, theory-based text messages for 90 days (270 unique scripted messages), evenly arrayed across the HIV Care Continuum. Text messages are delivered and transmitted to either a cell phone or an email inbox.

    Behavioral: Text Me, Alexis!

  • Experimental
    PHN and SMS

    PHN + SMS is the combined intervention. PHN is a peer navigation intervention to advance trans women through the HIV Care Continuum by identifying their individual needs and barriers to HIV care, including: substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence. Participants receive unlimited navigation sessions over 3 months; PHN sessions are delivered in a private room similar to a one-on-one peer counseling session. Text messages are scripted across: 1) HIV Care Continuum (HIV Positivity/Physical and Emotional Health, Linkage/Retention in HIV Care, and ART Adherence/Viral Load Suppression); and, 2) theoretical foundation (Social Support Theory, Social Cognitive Theory, or Health Belief Model). Participants receive three daily, theory-based text messages for 90 days (270 unique scripted messages), evenly arrayed across the HIV Care Continuum. Text messages are delivered and transmitted to either a cell phone or an email inbox.

    Behavioral: Text Me, Alexis!

Interventions

  • BehavioralText Me, Alexis!

    Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression

06

What researchers measure

Primary outcomes

  1. Rate of HIV Viral Load Suppression

    HIV virological suppression is defined as the undetectability threshold ˂200 copies/mL. Key indicators of HIV care will be regressed on treatment condition and a series of baseline and time-varying covariates. Responses at each timepoint will be considered nested within an individual, which is necessary to control for the violations of independence that can occur when repeated measurements are taken from the same individual.

    Time frame: 18 months

  2. Relative Cost Effectiveness

    The primary outcome of the cost-effectiveness analysis is the incremental cost-effectiveness ratio (ICER), which will be calculated as the incremental mean cost of a given intervention relative to an alternative, divided by the incremental mean effectiveness of the two interventions. Two types of ICERs will be calculated, one for each measure of effectiveness: a) The quality-adjusted life-year (QALY) is a measure that combines the health-related quality-of-life (HRQoL) associated with an individual's health state and their time spent in that state, and b) Advancement along the HIV Care Continuum. All measures of mean cost and effectiveness will be adjusted for important covariates. Relative cost-effectiveness will be assessed according to multiple decision-maker perspectives, and will be evaluated across a range of willingness-to-pay thresholds.

    Time frame: 18 months

Secondary outcomes

  1. Measurements of Heterogeneous Intervention Effects

    Individual-level demographic characteristics (e.g., age, race/ethnicity, time since HIV diagnosis) and treatment condition will be treated as level-2 independent variables within the hierarchical model as they are stable or intrinsic characteristics. Measurements of the social and structural determinants of health (e.g., poverty, housing/food insecurity, education, health insurance) will be included in the level-1 model as time-varying covariates because they are measured repeatedly and likely to change over the duration of the follow-up period. Lastly, an indicator of time (months since follow-up) will be included at level-1 as well. Level-2 covariates will be used to predict individual intercepts (that can be thought of as the 'starting point' for each participant), and treatment condition will be used to predict the slope of time (creating a time x intervention interaction term).

    Time frame: 18 months

07

Results

Posted Sep 2, 2026

Participant flow

Participant flow — Overall Study
MilestonePeer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMS
Started242423
Completed242423
Not completed000

Outcome measures

PrimaryRate of HIV Viral Load Suppression

HIV virological suppression is defined as the undetectability threshold ˂200 copies/mL. Key indicators of HIV care will be regressed on treatment condition and a series of baseline and time-varying covariates. Responses at each timepoint will be considered nested within an individual, which is necessary to control for the violations of independence that can occur when repeated measurements are taken from the same individual.

Time frame:
18 months
Reported as:
Count of participants · Participants
Rate of HIV Viral Load Suppression
ParticipantsPeer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMS
Rate of HIV Viral Load Suppression000
PrimaryRelative Cost Effectiveness

The primary outcome of the cost-effectiveness analysis is the incremental cost-effectiveness ratio (ICER), which will be calculated as the incremental mean cost of a given intervention relative to an alternative, divided by the incremental mean effectiveness of the two interventions. Two types of ICERs will be calculated, one for each measure of effectiveness: a) The quality-adjusted life-year (QALY) is a measure that combines the health-related quality-of-life (HRQoL) associated with an individual's health state and their time spent in that state, and b) Advancement along the HIV Care Continuum. All measures of mean cost and effectiveness will be adjusted for important covariates. Relative cost-effectiveness will be assessed according to multiple decision-maker perspectives, and will be evaluated across a range of willingness-to-pay thresholds.

Time frame:
18 months
Reported as:
Count of participants · Participants
Relative Cost Effectiveness
ParticipantsPeer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMS
Relative Cost Effectiveness000
SecondaryMeasurements of Heterogeneous Intervention Effects

Individual-level demographic characteristics (e.g., age, race/ethnicity, time since HIV diagnosis) and treatment condition will be treated as level-2 independent variables within the hierarchical model as they are stable or intrinsic characteristics. Measurements of the social and structural determinants of health (e.g., poverty, housing/food insecurity, education, health insurance) will be included in the level-1 model as time-varying covariates because they are measured repeatedly and likely to change over the duration of the follow-up period. Lastly, an indicator of time (months since follow-up) will be included at level-1 as well. Level-2 covariates will be used to predict individual intercepts (that can be thought of as the 'starting point' for each participant), and treatment condition will be used to predict the slope of time (creating a time x intervention interaction term).

Time frame:
18 months
Reported as:
Count of participants · Participants
Measurements of Heterogeneous Intervention Effects
ParticipantsPeer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMS
Measurements of Heterogeneous Intervention Effects000

Adverse events

Collected over Trial was terminated before any participants could complete the trial. Adverse Events were monitored through study completion, up to 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peer Health Navigation (PHN)0/24 (0%)0/24 (0%)0/24 (0%)
Simple Message System (SMS [Text Messaging])0/24 (0%)0/24 (0%)0/24 (0%)
PHN and SMS0/23 (0%)0/23 (0%)0/23 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Peer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMSTotal
Mean50.7 ± 11.450.2 ± 11.447.6 ± 10.949.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Peer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMSTotal
Female24242371
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Peer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMSTotal
Hispanic or Latino19181855
Not Hispanic or Latino46515
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Peer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMSTotal
American Indian or Alaska Native0202
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American34512
White19181855
More than one race1001
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Peer Health Navigation (PHN)Simple Message System (SMS [Text Messaging])PHN and SMSTotal
United States24242371
08

Study locations

1 site
  • Friends Community Center
    Los Angeles, California 90028, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 12, 2024
  • Informed consent form · May 17, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — No current plan to share individual participant data.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06408350
Lead sponsor
Friends Research Institute, Inc.
Collaborators
Weill Medical College of Cornell University
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Apr 11, 2024
Primary completion
Mar 19, 2025
Completion
Mar 19, 2025
Results posted
Sep 2, 2026
Last update
Sep 2, 2026

Study contacts

Cathy J Reback, PhD
principal investigator · Friends Research Institute, Inc.
Sean M Murphy, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion